May Case of the Month

Clinical History:A 57-year-old woman with stage IV lung adenocarcinoma (Figure 1) with an EGFR L858R mutation was treated with erlotinib (an EGFR tyrosine kinase inhibitor). After initial response to treatment for over 1 year, she developed extensive metastatic disease at the T5 vertebra (biopsy shown in Figure 2). By immunohistochemistry, the tumor labeled for CAM 5.2, TTF-1, synaptophysin, and chromogranin A (Figure 3). The Ki-67 (MIB-1) labeling index was over 70% (Figure 4).

Click here to see more.













Renew or Apply On Line
Upcoming Meetings

ASCP - Update in Pulmonary Pathology: Contemporary Classification & Diagnosis

Dr. Andrew Churg, Director

May 10 - 12, 2018
Chicago, IL

Co-sponsored by PPS

Registration and information

Program (pdf)

Thoracic Pathology Update

Drs. Mari Mino-Kenudson & WilliamTravis, Co-directors

June 22 - 24, 2018, 2018
Massachussets General Hospital Boston, MA

Co-sponsored by PPS

Registration and information

Program (pdf)

International Academy of Pathology Meeting (IAP)

October 14-18, 2018
Dead Sea NR, Amman, Jordan

Program of pulmonary sessions

IAP website

Save the Date!

Pulmonary Pathology Society
Biennial Meeting

June 26-June 28, 2019
Dubrovnik, Croatia




 


facebook  twitter ...
2017 PPS Lifetime Achievement Award
Professor Thomas Colby
Copyright © 2018, PPS, all rights reserved.
For questions or comments, please contact webmaster@pulmonarypath.org